ANGO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AN

Mkt Cap

$473.2M

Volume

717.16K

Loading chart

AN

ANGOAngioDynamics, Inc.

ANGO

Pay with—

Available Balance0.00

AN

Mkt Cap

$472.7M

Volume

717.15K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YAngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.Zacks Investment Research · Oct 9, 2026

AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue EstimatesAngioDynamics reported a quarterly loss of $0.04 per share, beating consensus estimates of $0.10 loss by 60%, but missed revenue expectations with $80.92 million versus the estimated $81.85 million. The medical device company has a Zacks Rank #3 (Hold) rating with mixed estimate revisions. The Medical-Instruments industry ranks in the top 39% of Zacks industries.Zacks Investment Research · Oct 8, 2026

Atherectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036A comprehensive market analysis report on atherectomy devices covering 39 countries with forecasts through 2036. The market is driven by the shift toward minimally-invasive techniques for treating coronary and peripheral artery diseases, replacing traditional bypass surgery. The report provides detailed market segmentation, intervention volumes, competitive dynamics, and regulatory insights across developed markets.GlobeNewswire Inc. · Jan 16, 2026

Why AngioDynamics Stock Is Sinking TodayAngioDynamics shares fell 13.1% despite posting strong Q3 results with revenue of $79.4 million (beating estimates) and better-than-expected earnings. The sell-off was triggered by the unexpected announcement of CEO Jim Clemmer's retirement after 10 years leading the company. While the board has formed a search committee to find a successor and the company raised its 2026 guidance, investor uncertainty about leadership transition overshadowed the positive business fundamentals.The Motley Fool · Jan 6, 2026

Why Did AngioDynamics Stock Pop Today?AngioDynamics reported Q1 fiscal 2026 results with mixed performance, beating adjusted earnings expectations but showing ongoing challenges in profitability. The company saw 12% overall sales growth, driven by med tech segment, but remains years away from consistent profitability.The Motley Fool · Oct 2, 2025

3 Stocks Insiders Are Buying Heavily in October and WhyInsiders have been making significant purchases in Eton Pharmaceuticals, AngioDynamics, and Tile Shop Holdings, indicating their confidence in these companies' prospects.Investing.com · Oct 9, 2024

AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAngioDynamics (ANGO) has seen a 15.9% decline in the past four weeks, but its oversold RSI and improved earnings estimates suggest a potential turnaround may be on the horizon.Benzinga · Oct 8, 2024

Why AngioDynamics Stock Is Crashing TodayAngioDynamics, a medical technology company, reported mixed results for its fiscal Q1, with revenue slightly missing estimates but adjusted loss per share better than expected. The company maintained its full-year guidance, but its growth prospects are not seen as exciting compared to other stocks.The Motley Fool · Oct 3, 2024

AngioDynamics stock target raised on growth prospects - Investing.comOppenheimer raised its price target for AngioDynamics stock to $13 from $12, citing the company's strong fourth-quarter sales, particularly in its higher-margin and growth segments. The firm also noted AngioDynamics' efforts to expand EBITDA and reach profitability by fiscal year 2027.Investing.com · Jul 16, 2024

U.S. Autoimmune Disease Diagnostics (Systemic, Localized) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswireThe U.S. autoimmune disease diagnostics market is expected to reach $3.01 billion by 2030, driven by the rising incidence of autoimmune diseases and advancements in diagnostic technologies. Localized autoimmune disease diagnostics and antinuclear antibody tests are expected to dominate the market.GlobeNewswire Inc. · Jul 11, 2024

to start trading

AN

ANGOAngioDynamics, Inc.

ANGO

Pay with—

Available Balance0.00

Your PositionYou don't own any ANGO yet.

Related Tickers

Earnings